| Literature DB >> 33452333 |
Lara Duran-Trio1, Gabriella Fernandes-Pires1, Dunja Simicic2, Jocelyn Grosse3, Clothilde Roux-Petronelli1, Stephen J Bruce1, Pierre-Alain Binz1, Carmen Sandi3, Cristina Cudalbu2, Olivier Braissant4.
Abstract
Creatine is an organic compound used as fast phosphate energy buffer to recycle ATP, important in tissues with high energy demand such as muscle or brain. Creatine is taken from the diet or endogenously synthetized by the enzymes AGAT and GAMT, and specifically taken up by the transporter SLC6A8. Deficit in the endogenous synthesis or in the transport leads to Cerebral Creatine Deficiency Syndromes (CCDS). CCDS are characterized by brain creatine deficiency, intellectual disability with severe speech delay, behavioral troubles such as attention deficits and/or autistic features, and epilepsy. Among CCDS, the X-linked creatine transporter deficiency (CTD) is the most prevalent with no efficient treatment so far. Different mouse models of CTD were generated by doing long deletions in the Slc6a8 gene showing reduced brain creatine and cognitive deficiencies or impaired motor function. We present a new knock-in (KI) rat model of CTD holding an identical point mutation found in patients with reported lack of transporter activity. KI males showed brain creatine deficiency, increased urinary creatine/creatinine ratio, cognitive deficits and autistic-like traits. The Slc6a8Y389C KI rat fairly enriches the spectrum of CTD models and provides new data about the pathology, being the first animal model of CTD carrying a point mutation.Entities:
Year: 2021 PMID: 33452333 PMCID: PMC7810893 DOI: 10.1038/s41598-020-80824-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379